News
Consolidation Durvalumab Alone or Combined With Oleclumab or Monalizumab for Unresectable Stage III NSCLC
In an interim analysis of the phase II COAST trial reported in the Journal of Clinical Oncology, Roy S. Herbst, MD, PhD, FACP, FASCO, and colleagues found that consolidation durvalumab in combination with the anti-CD73 antibody oleclumab or anti-NKG2A antibody monalizumab both improved objective response rate and progression-free survival vs durvalumab alone among patients with unresectable stage III non–small cell lung cancer (NSCLC) without disease progression following definitive platinum-based concurrent chemoradiotherapy.
Source: ASCO Post